WO2024023710A1 - Compositions pharmaceutiques de tafamidis - Google Patents

Compositions pharmaceutiques de tafamidis Download PDF

Info

Publication number
WO2024023710A1
WO2024023710A1 PCT/IB2023/057546 IB2023057546W WO2024023710A1 WO 2024023710 A1 WO2024023710 A1 WO 2024023710A1 IB 2023057546 W IB2023057546 W IB 2023057546W WO 2024023710 A1 WO2024023710 A1 WO 2024023710A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
pharmaceutical composition
tafamidis
free acid
microcrystalline cellulose
Prior art date
Application number
PCT/IB2023/057546
Other languages
English (en)
Inventor
John Edward KRESEVIC
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2024023710A1 publication Critical patent/WO2024023710A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Transthyretin (ATTR) amyloidosis is rare, progressive disease characterized by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein in the body’s organs and tissues. ATTR amyloidosis can impact numerous organs and tissues in the body, including the peripheral nervous system, and organs such as the heart, kidneys, gastrointestinal tract and eyes.
  • Transthyretin cardiomyopathy (ATTR- CM) and transthyretin polyneuropathy (ATTR-PN) are two presentations of the disease. ATTR-CM affects the heart and leads to restrictive cardiomyopathy and progressive heart failure.
  • ATTR-CM There are two sub-types of ATTR-CM: hereditary, which is caused by a mutation in the transthyretin gene and can occur in people as early as their 50s and 60s; or the wild-type form which is associated with aging, and is thought to be more common, usually affecting men after age 60. Often ATTR-CM is diagnosed only after symptoms have become severe. ATTR-PN results from a genetic mutation of the transthyretin gene causing amyloid fibrils to form in the peripheral and autonomic nerves. ATTR-PN typically occurs during active adult years with onset as early as the 30s in some patients, followed by disease progression that may reach the terminal stage in approximately 10 years on average from disease onset.
  • Tafamidis sold under the brand names Vyndaqel® and Vyndamax®, is an oral transthyretin stabilizer medication used for the treatment of adults with certain forms of transthyretin amyloidosis.
  • Tafamidis can be used to treat both hereditary forms as well as wild-type transthyretin amyloidosis.
  • Tafamidis works by selectively binding to transthyretin and stabilizes the quaternary structure of the tetrameric transthyretin protein and slowing the formation of amyloid.
  • Tafamidis free acid can be prepared by methods such as those described in US Patent 7,214,695, WO 04056315, US 9,770,441 and WO 2016/038500.
  • the present invention provides oral pharmaceutical compositions comprising tafamidis free acid.
  • the oral pharmaceutical compositions comprise tafamidis free acid in an oral tablet dosage form.
  • the present invention particularly provides immediate release tablet formulations of tafamidis free acid wherein the tablet may be film-coated.
  • Tafamidis is formulated as a common blend to make immediate release tablet cores, which can then be film-coated to make film-coated tablets, such as 12.2 mg tafamidis free acid and 61 mg tafamidis free acid tablet drug products.
  • the tafamidis 12.2 mg and 61 mg film-coated tablets have been formulated for immediate release for the oral treatment of transthyretin amyloidosis diseases such as ATTR-CM and ATTR-PN.
  • the tablet cores are made from a common blend using a dry granulation process and can then be film-coated by a batch process to provide the film- coated tablet drug product.
  • E1 is a pharmaceutical composition which is a tablet comprising tafamidis free acid, one or more diluents, 7-9% (w/w%) disintegrant and a lubricant.
  • E2 is the pharmaceutical composition of E1 which is a tablet wherein the disintegrant is crospovidone.
  • E3 is the pharmaceutical composition of E1 or E2 which is a tablet wherein the disintegrant is crospovidone type b.
  • E4 is the pharmaceutical composition of any one of E1 to E3 which is a tablet wherein the one or more diluents are selected from microcrystalline cellulose and lactose monohydrate.
  • E5 is the pharmaceutical composition of any one of E1 to E4 which is a tablet wherein the lubricant is magnesium stearate.
  • E6 is the pharmaceutical composition of any one of E1 to E5 which is a tablet comprising about 8% (w/w%) crospovidone type b.
  • E7 is the pharmaceutical composition of any one of E1 to E6 which is a tablet comprising about 11.6% (w/w%) tafamidis free acid.
  • E8 is the pharmaceutical composition of any one of E1 to E7 which is a tablet comprising 12.2 mg tafamidis free acid.
  • E9 is the pharmaceutical composition of any one of E1 to E7 which is a tablet comprising 61 mg tafamidis free acid.
  • E10 is the pharmaceutical composition of any one of E1 to E9 which is a tablet comprising about 79.65% (w/w%) of one or more diluents which are selected from microcrystalline cellulose and lactose monohydrate.
  • E11 is the pharmaceutical composition of any one of E1 to E10 which is a tablet comprising about 53.1% (w/w%) microcrystalline cellulose and about 26.55% lactose monohydrate.
  • E12 is the pharmaceutical composition of any one of E1 to E11 which is a tablet comprising about 0.75% (w/w%) of magnesium stearate.
  • E13 is the pharmaceutical composition of any one of E1 to E12 wherein the tablet is film coated.
  • E14 is the pharmaceutical composition of E13 wherein the tablet film coating comprises hydroxypropyl methylcellulose and lactose.
  • E15 is the pharmaceutical composition of E13 or E14 wherein the tablet film coating is about 4% (w/w) of the overall weight of the film coated tablet.
  • E16 is a pharmaceutical composition which is a tablet comprising about 11.6% (w/w%) tafamidis free acid; about 53.1% (w/w%) microcrystalline cellulose; about 26.55% (w/w%) lactose monohydrate; about 8.0% (w/w%) crospovidone type b and about 0.75% (w/w%) magnesium stearate.
  • E17 is a pharmaceutical composition which is a tablet comprising 11.6% ⁇ 0.1% (w/w%) tafamidis free acid; 53.1% ⁇ 0.1% (w/w%) microcrystalline cellulose; 26.55% ⁇ 0.1% (w/w%) lactose monohydrate; 8.0% ⁇ 0.1% (w/w%) crospovidone type b and 0.75% ⁇ 0.1% (w/w%) magnesium stearate.
  • E18 is the pharmaceutical composition of E16 or E17 wherein the tablet is film coated.
  • E19 is the pharmaceutical composition of any one of E16 to E18 wherein the tablet film coating comprises hydroxypropyl methylcellulose and lactose.
  • E20 is the pharmaceutical composition of E18 or E19 wherein the tablet film coating is 4.0% ⁇ 0.1% (w/w%) of the overall weight of the film coated tablet.
  • E21 is a pharmaceutical composition which is a tablet comprising about 12.20 mg tafamidis free acid, about 55.85 mg microcrystalline cellulose, about 27.92 mg lactose monohydrate, about 8.42 mg crospovidone type b and about 0.79 mg magnesium stearate.
  • E22 is the pharmaceutical of E21 which is a tablet comprising 12.20 mg tafamidis free acid, 55.85 mg microcrystalline cellulose, 27.92 mg lactose monohydrate, 8.42 mg crospovidone type b and 0.79 mg magnesium stearate.
  • E23 is the pharmaceutical composition of E21 or E22 wherein the tablet is film coated.
  • E24 is the pharmaceutical composition of E23 wherein tablet film coating comprises hydroxypropyl methylcellulose and lactose.
  • E25 is the pharmaceutical composition of E23 or E24 wherein the tablet film coating weighs 4.21 mg.
  • E26 is a pharmaceutical composition which is a tablet comprising about 61.00 mg tafamidis free acid, about 279.25 mg microcrystalline cellulose, about 139.6 mg lactose monohydrate, about 42.10 mg crospovidone type b and about 2.95 mg magnesium stearate.
  • E27 is the pharmaceutical composition of E26 which is a tablet comprising 61.00 mg tafamidis free acid, 279.25 mg microcrystalline cellulose, 139.6 mg lactose monohydrate, 42.10 mg crospovidone type b and 2.95 mg magnesium stearate.
  • E28 is the pharmaceutical composition of E26 or E27 wherein the tablet is film coated.
  • E29 is the pharmaceutical composition of E28 wherein the tablet film coating comprises hydroxypropyl methylcellulose and lactose.
  • E30 is the pharmaceutical composition of E28 or E29 wherein the tablet film coating weighs 21.05 mg.
  • E31 is the pharmaceutical composition of any one of E1 to E7 which is a tablet comprising about 13.0 mg, about 13.5 mg, about 14.0 mg, about 14.5 mg, about 15.0 mg, about 15.5 mg, about 59.0 mg, about 60.0 mg or about 62 mg tafamidis free acid.
  • E32 is the pharmaceutical composition of E31 which is a tablet comprising 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 59.0 mg, 60.0 mg or 62.0 mg of tafamidis free acid.
  • E33 is the pharmaceutical composition of E32 which is a tablet comprising 13.0 mg tafamidis free acid.
  • E34 is the pharmaceutical composition of E33 which is a tablet comprising 13.0 mg tafamidis free acid, 59.51 mg microcrystalline cellulose, 29.75 mg lactose monohydrate, 8.98 mg crospovidone type b and 0.85 mg magnesium stearate.
  • E35 is the pharmaceutical composition of E32 which is a tablet comprising 13.5 mg tafamidis free acid.
  • E36 is the pharmaceutical composition of E35 which is a tablet comprising 13.5 mg tafamidis free acid, 61.80 mg microcrystalline cellulose, 30.89 mg lactose monohydrate, 9.32 mg crospovidone type b and 0.88 mg magnesium stearate.
  • E37 is the pharmaceutical composition of E32 which is a tablet comprising 14.0 mg tafamidis free acid.
  • E38 is the pharmaceutical composition of E37 which is a tablet comprising 14.0 mg tafamidis free acid, 64.09 mg microcrystalline cellulose, 32.04 mg lactose monohydrate, 9.66 mg crospovidone type b and 0.91 mg magnesium stearate.
  • E39 is the pharmaceutical composition of E32 which is a tablet comprising 14.5 mg tafamidis free acid.
  • E40 is the pharmaceutical composition of E39 which is a tablet comprising 14.5 mg tafamidis free acid, 66.38 mg microcrystalline cellulose, 33.18 mg lactose monohydrate, 10.00 mg crospovidone type b and 0.94 mg magnesium stearate.
  • E41 is the pharmaceutical composition of E32 which is a tablet comprising 15.0 mg tafamidis free acid.
  • E42 is the pharmaceutical composition of E41 which is a tablet comprising 15.0 mg tafamidis free acid, 68.69 mg microcrystalline cellulose, 34.33 mg lactose monohydrate, 10.36 mg crospovidone type b and 0.97 mg magnesium stearate.
  • E43 is the pharmaceutical composition of E32 which is a tablet comprising 15.5 mg tafamidis free acid.
  • E44 is the pharmaceutical composition of E43 which is a tablet comprising 15.5 mg tafamidis free acid, 70.96 mg microcrystalline cellulose, 35.47 mg lactose monohydrate, 10.70 mg crospovidone type b and 1.00 mg magnesium stearate.
  • E45 is the pharmaceutical composition of E32 which is a tablet comprising 59.0 mg tafamidis free acid.
  • E46 is the pharmaceutical composition of E45 which is a tablet comprising 59.0 mg tafamidis free acid, 270.09 mg microcrystalline cellulose, 135.02 mg lactose monohydrate, 40.72 mg crospovidone type b and 3.82 mg magnesium stearate.
  • E47 is the pharmaceutical composition of E32 which is a tablet comprising 60.0 mg tafamidis free acid.
  • E48 is the pharmaceutical composition of E47 which is a tablet comprising 60.0 mg tafamidis free acid, 274.67 mg microcrystalline cellulose, 137.31 mg lactose monohydrate, 41.40 mg crospovidone type b and 3.89 mg magnesium stearate.
  • E49 is the pharmaceutical composition of E32 which is a tablet comprising 62.0 mg tafamidis free acid.
  • E50 is the pharmaceutical composition of E49 which is a tablet comprising 62.0 mg tafamidis free acid, 283.83 mg microcrystalline cellulose, 141.89 mg lactose monohydrate, 42.80 mg crospovidone type b and 4.01 mg magnesium stearate.
  • E51 is the pharmaceutical composition of any one of E31 to E50 wherein the tablet is film coated.
  • E52 is the pharmaceutical composition of E51 wherein the tablet film coating comprises hydroxypropyl methylcellulose and lactose.
  • E53 is the pharmaceutical composition of E52 wherein the tablet film coating is about 4% (w/w) of the overall weight of the film coated tablet.
  • E54 is a method of treating transthyretin amyloidosis in a patient comprising administering a pharmaceutical composition according to any one of E1 to E53 to the patient.
  • E55 is the method of claim 54 wherein the transthyretin amyloidosis is transthyretin cardiomyopathy (ATTR-CM) or transthyretin polyneuropathy (ATTR-PN).
  • TRR-CM transthyretin cardiomyopathy
  • ATTR-PN transthyretin polyneuropathy
  • E56 is the use of a pharmaceutical composition according to any one of E1 to E53 for treatment of transthyretin amyloidosis.
  • E57 is the use according to E56 wherein the transthyretin amyloidosis is transthyretin cardiomyopathy (ATTR-CM) or transthyretin polyneuropathy (ATTR-PN).
  • TRR-CM transthyretin cardiomyopathy
  • ATTR-PN transthyretin polyneuropathy
  • Figure 1 Flow Diagram of Manufacturing Process for Tafamidis 12.2 mg and 61.0 mg Film-Coated Tablets.
  • the excipients used in the tafamidis tablet or film-coated tablet are globally acceptable and all but crospovidone are present at precedented levels in the formulation.
  • the amount of tablet ingredients can be expressed as weight percent of the tablet (i.e. w/w%). It is to be used that the term about can be plus or minus 0.2% or alternatively 0.1% (i.e. ⁇ 0.2% or ⁇ 0.1%).
  • Crospovidone is typically used at a 1-5% (w/w %) level and an advantageous embodiment of the tafamidis common blend used to prepare the tablet core of the present invention contains 8% crospovidone.
  • Crospovidone was evaluated at 4, 6, 8 and 10% (w/w%) levels during development and the microcrystalline cellulose/lactose monohydrate diluents were adjusted accordingly to manage the tablet core weight.
  • Crospovidone is included in the tablet core formulation as a disintegrant in the oral tablets. Adding the disintegrant promotes tablet disintegration and adding in the extra-granular portion after roller compaction is completed acts as a disintegrant as well as a dry binder.
  • Magnesium stearate is included in the tablet core formulation as a lubricant in the tablets. Magnesium stearate is used as a lubricant in the tablet core formulation to aid in tablet compression.
  • Opadry® II yellow and Opadry® II white are proprietary film coating systems used for the 12.2 mg and 61 mg tablets, respectively.
  • Table A Estimated Cmax and ALICinf ratio of dose-adjusted tafamidis free acid tablet (test) to 20 mg meglumine capsule (reference) calculated by clinical data observed in B3461103.
  • the potential dose adjustment range for low dose tafamidis FA tablet (equivalent to 20 mg tafamidis MS capsule) is estimated to be 12.2 mg to 16 mg as the estimated Cmax and ALICinf ratios are within 0.8-1.25. A more conservative estimate would set the dose range between 13 mg to 15.5 mg as the estimated Cmax and ALICinf ratios would be within 0.85-1.20.
  • the estimated Cmax and ALICinf ratios can be calculated using the clinical data obtained in Study B3461030 (48.8 mg tafamidis FA tablet vs 4 x 20 mg tafamidis MS capsules) and Study B3461051 (48.8 mg tafamidis FA tablet or 58 mg tafamidis free acid tablet vs. 4 x 20 mg tafamidis MS capsules).
  • the estimated Cmax and ALICinf ratios of tafamidis FA tablet with various strengths to 4 x 20 mg tafamidis MS capsules are listed in Table B.
  • the dose adjustment range for high dose tafamidis FA tablet (equivalent to 4 x 20 mg meglumine salt capsule) is estimated to be 51 mg to 70 mg as the estimated Cmax and ALICinf ratios are within 0.8 - 1.25.
  • the dose adjustment range is estimated to be 53 mg to 67 mg using the observed rBA data of the 48.8 mg tafamidis FA tablet in Study B3461051 (Table B2), and 56 mg to 65 mg using the observed rBA data of the 58 mg tafamidis FA tablet in Study B3461051 (Table B3).
  • the acceptance criteria of Cmax and ALICinf ratios can be set at 0.85 - 1.20.
  • the potential dose adjustment range is estimated to be 51 - 67 mg using the 48.8 mg tafamidis FA tablet rBA data from Study B3461030 (Table B), 56 - 64 mg using the 48.8 mg tafamidis FA tablet rBA data from Study B3461051 (Table B2), and 59 - 62 mg using the 58 mg tafamidis FA tablet rBA data from study B3461051 (Table B3).
  • this dose adjustment range could be preferable.
  • the observed clinical data suggests that the dose adjustment range of high dose tafamidis FA tablet is likely between 51 mg to 70 mg.
  • This dose range include all the estimated ranges calculated by the methods described above. Within this dose adjustment range, 59 mg to 62 mg is preferable because it is the intersection of all the estimated ranges.
  • Table B Estimated Cmax and ALICinf ratio between dose-adjusted tafamidis free acid tablet (test) and 4 x 20 mg meglumine capsules (reference).
  • Table B2 Cmax and ALICinf ratio calculated using rBA data between 48.8 mg tafamidis free acid tablet and 4 x 20 mg tafamidis meglumine salt capsules in study 1051
  • Table B3 Cmax and ALICinf ratio calculated using rBA data between 58 mg tafamidis free acid tablet and 4 x 20 mg tafamidis meglumine salt capsules in study 1051
  • Formulation Tafamidis is formulated as a common blend to make immediate release tablet cores such as 12.2 mg and 61 mg immediate release tablet cores.
  • the formulation provided in Table 1 , is composed of microcrystalline cellulose and lactose monohydrate (diluents), crospovidone (disintegrant), and magnesium stearate (lubricant).
  • Commercial tafamidis tablet cores are manufactured using a dry granulation manufacturing platform followed by a film coating step. Tablets are film coated with an appropriate coating.
  • the tablets can be coated with hydroxypropyl methylcellulose I lactose based Opadry® II formulation with yellow color for the 12.2 mg tablets and white color for the 61 mg tablets.
  • the preceding procedure is used in an analogous manner to prepare the tablet cores which contain 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 59.0 mg, 60 mg or 62.0 mg of tafamidis and to coat those cores with 4% by weight of film coating.
  • Examples 1 and 2 were prepared using the General Procedure for Tablet Preparation as described above. Table 1: Examples 1 and 2 - Composition of Tafamidis 12.2 mg and 61 mg Film-Coated
  • the above tablet was prepared in a manner analogous to the General Method described above for Examples 1 and 2. In studies this formulation failed to exhibit equivalent properties to the 20 mg tafamidis meglumine gel capsule and therefore was determined to be not viable as a commercially acceptable formulation.
  • Table 1A Examples 3 and 4 - Composition of Tafamidis 13.0 mg and 13.5 mg Film- Coated Tablets using 8% (w/w) Disintegrant Crospovidone Type B a Intra-granular b Extra-granular c non-bovine
  • Table 1B Examples 5 and 6 - Composition of Tafamidis 14.0 mg and 14.5 mg Film- Coated Tablets using 8% (w/w) Disintegrant Crospovidone Type B a Intra-granular b Extra-granular c non-bovine Table 1C: Examples 7 and 8 - Composition of Tafamidis 15.0 mg and 15.5 mg Film-

Abstract

La présente invention concerne une composition pharmaceutique qui est un comprimé comprenant de l'acide libre de tafamidis, un ou plusieurs diluants, de 7 à 9 % (p/p %) de délitant et un lubrifiant. Un exemple représentatif est un comprimé comprenant environ 11,6 % (p/p %) d'acide libre de tafamidis ; environ 53,1 % (p/p %) de cellulose microcristalline ; environ 26,55 % 5 (p/p %) de monohydrate de lactose ; environ 8,0 % (p/p %) de crospovidone de type b et environ 0,75 % (p/p %) de stéarate de magnésium.
PCT/IB2023/057546 2022-07-28 2023-07-25 Compositions pharmaceutiques de tafamidis WO2024023710A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263369696P 2022-07-28 2022-07-28
US63/369,696 2022-07-28
US202363514038P 2023-07-17 2023-07-17
US63/514,038 2023-07-17

Publications (1)

Publication Number Publication Date
WO2024023710A1 true WO2024023710A1 (fr) 2024-02-01

Family

ID=87571092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/057546 WO2024023710A1 (fr) 2022-07-28 2023-07-25 Compositions pharmaceutiques de tafamidis

Country Status (1)

Country Link
WO (1) WO2024023710A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (fr) 2002-12-19 2004-07-08 The Scripps Research Institute Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2011116123A1 (fr) * 2010-03-19 2011-09-22 Irm Llc Tafamidis pour le traitement de troubles ophtalmiques
WO2016038500A1 (fr) 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
WO2020128816A2 (fr) * 2018-12-20 2020-06-25 Pfizer Inc. Compositions pharmaceutiques et méthodes comprenant une combinaison d'un stabilisateur de transthyrétine benzoxazole et d'un agent thérapeutique supplémentaire
WO2020232325A1 (fr) * 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Formes solides de tafamidis et sels associés
US20210363116A1 (en) * 2019-11-15 2021-11-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of tafamidis and preparation method therefor and use thereof
US11523993B1 (en) * 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
US20230149365A1 (en) * 2021-11-18 2023-05-18 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
US20230149366A1 (en) * 2021-11-18 2023-05-18 Nuray Chemicals Private Limited Solid dosage forms of tafamidis
WO2023091534A1 (fr) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Forme à l'état solide de tafamidis

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (fr) 2002-12-19 2004-07-08 The Scripps Research Institute Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
US7214695B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2011116123A1 (fr) * 2010-03-19 2011-09-22 Irm Llc Tafamidis pour le traitement de troubles ophtalmiques
WO2016038500A1 (fr) 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
US9770441B1 (en) 2014-09-08 2017-09-26 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
WO2020128816A2 (fr) * 2018-12-20 2020-06-25 Pfizer Inc. Compositions pharmaceutiques et méthodes comprenant une combinaison d'un stabilisateur de transthyrétine benzoxazole et d'un agent thérapeutique supplémentaire
WO2020232325A1 (fr) * 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Formes solides de tafamidis et sels associés
US20210363116A1 (en) * 2019-11-15 2021-11-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of tafamidis and preparation method therefor and use thereof
WO2023091534A1 (fr) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Forme à l'état solide de tafamidis
US11523993B1 (en) * 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
US20230149365A1 (en) * 2021-11-18 2023-05-18 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
US20230149366A1 (en) * 2021-11-18 2023-05-18 Nuray Chemicals Private Limited Solid dosage forms of tafamidis

Similar Documents

Publication Publication Date Title
AU2007251471B2 (en) New form of administration of racecadotril
JPH0753364A (ja) 高及び低粘度のｈｐｍｃを用いた持続性の放出
US11426383B2 (en) Tesofensine and beta blocker combination formulations
JP2012514623A (ja) １またはそれ以上のフマル酸エステルを含む医薬組成物
HU226595B1 (en) Modified release multiple-units dosage composition
TW200814992A (en) Stabilized pharmaceutical compositions comprising fesoterodine
AU2019203327A1 (en) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN111918646B (zh) 延迟释放去铁酮片剂及其使用方法
JPS61500225A (ja) 点眼剤組成物
US20040142033A1 (en) Pharmaceutical composition, containing oxcarbazepine with sustained release of an active-ingredient
CN113018273A (zh) 一种固体制剂及其制备方法和用途
JP2008534451A (ja) めまいに対するペレット状の徐放型調製物
JP5823401B2 (ja) 不快な味が遮蔽された薬物含有膜被覆粒子
US20160228386A1 (en) Pharmaceutical Formulation
EP0869783B1 (fr) Comprime a liberation rapide contenant de l'acide tolfenamique ou un sel pharmaceutiquement acceptable dudit acide
WO2024023710A1 (fr) Compositions pharmaceutiques de tafamidis
WO2020144146A1 (fr) Tesofensine pour la réduction du poids corporel chez des patients prader-willi
JP4562797B1 (ja) 沈降炭酸カルシウムを有効成分とする口腔内崩壊錠
TW202412774A (zh) 嗒伐咪迪(Tafamidis)的醫藥組合物
JP3552285B2 (ja) 経口コレステロール低下剤
KR101850350B1 (ko) 경구용 서방출 젤리제제 및 이의 제조방법
CN108066297A (zh) 治疗老年痴呆症的定位释放美金刚口腔崩解片组合物
US20240100011A1 (en) Pediatric formulations of ferric citrate
WO2023002004A1 (fr) Composition pharmaceutique multiparticulaire
CA3058933A1 (fr) Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23754411

Country of ref document: EP

Kind code of ref document: A1